CTLA4 and cancer: Up to date the immunotherapeutic effects have been achieved through the antagonistic activity of the anti-CTLA-4 antibodies, i.e., blocking the checkpoint that can prevent autoimmunity and immune responses against cancer [45], thus making it difficult to achieve cancer immunity without irAEs.